Lung Cancer's New Face: Women, Non-Smokers Targeted

The landscape of lung cancer is changing, with a notable increase in diagnoses among women, never-smokers, and younger populations over the past 15 years. Lung cancer has emerged as the leading cause of cancer-related deaths in women, exceeding deaths from breast, ovarian, and colorectal cancers annually. While lung cancer rates have significantly risen for women over the last 44 years, they have decreased for men, with more young women now diagnosed than men.

Recent public diagnoses, such as Pope Leo XIV's on October 13, 2026, have drawn attention to lung cancer in individuals who do not smoke. Factors like environmental exposures and genetics are being explored as potential causes. Early-stage detection, as seen in the Pope's case, allows for surgical treatment and potential cure. However, challenges persist as current screening guidelines do not typically include never-smokers, often leading to incidental tumor discovery.

Researchers are investigating why lung cancer rates are climbing among women. Delayed smoking initiation compared to men, coupled with early adoption of filtered cigarettes, may have contributed to a rise in adenocarcinoma. Some studies suggest women might be more susceptible to the carcinogenic effects of tobacco and second-hand smoke. Approximately 20% of women diagnosed with lung cancer have never smoked.

Beyond smoking, other risk factors include family history, and exposure to asbestos, radon, and air pollution. Workplace carcinogens and the effects of e-cigarette and marijuana smoke are also areas of concern. Genetic predispositions and susceptibility genes are increasingly recognized as playing a role in some lung cancer cases, offering potential for new early detection biomarkers.

In 2021, U.S. lung cancer screening guidelines were updated to include younger individuals with less smoking history, recommending screening for adults aged 50-80 with specific smoking histories. Despite these updates, lung cancer screening uptake remains low among eligible individuals. Advances in targeted therapies and immunotherapies have improved patient prognosis, with women often showing better outcomes, particularly never-smokers with specific molecular tumor changes.

Recognizing lung cancer symptoms in women, such as fatigue or pain, can be challenging as they may be attributed to other ailments. Expanding screening eligibility and genetic biomarker testing are crucial steps in addressing the growing global incidence of lung cancer, especially among women.